Frequently Asked Questions

Recurrence in HS is not random — it follows an underlying pattern that most standard treatments do not address. Antibiotics reduce bacterial load temporarily; surgery removes the existing lesion; but neither corrects the internal imbalance that continues generating new lesions.

When the root drivers — gut dysfunction, hormonal imbalance, chronic inflammation, and immune dysregulation — remain unaddressed, the condition has everything it needs to continue. The lesions you see are the end-stage expression of processes that began much deeper.

HS is not permanent if the underlying causes are identified and corrected in a structured, sustained way. Many patients have lived with HS for years under the assumption that management is the only option — that flares must simply be controlled and endured.

Remission is achievable. It requires internal correction — not just surface treatment — and it requires time. The deeper and longer the disease has been active, the more time the correction phase typically takes. But the disease process itself is reversible when approached correctly.

HS is not a skin disease in origin — it is a systemic condition with skin as its most visible expression. The five primary internal drivers identified through EPOH's clinical framework are: gut dysfunction and dysbiosis, hormonal imbalance (particularly androgens), insulin resistance and metabolic dysfunction, chronic low-grade inflammation, and immune dysregulation.

Most patients have more than one driver active simultaneously. The relative weight of each driver varies between individuals — which is why the same treatment works differently in different patients, and why personalised assessment matters.

Surgery can be appropriate for specific, advanced structural problems — particularly large, established sinus tracts that are unlikely to resolve through internal treatment alone. In those cases, it removes existing tissue damage.

What surgery does not do is address why new lesions form. Patients who undergo surgical excision without concurrent internal treatment consistently report recurrence — often in the same area or adjacent regions — within months. Surgery is a structural intervention in a systemic disease. It addresses the outcome, not the cause.

Early signs of improvement are typically subtle but consistent — less heat in lesion areas, shorter flare durations, reduced pain intensity, fewer food-trigger reactions. These usually begin to appear within four to eight weeks of Phase 1 treatment, depending on disease history and severity.

Deeper structural changes — reduction in tunnel activity, scar stabilisation, hormonal correction — take longer. This is not a treatment that suppresses symptoms quickly; it is one that addresses what is driving them. That correction is gradual by design.

In most cases, yes — the EPOH approach works through internal correction of root causes rather than suppression of symptoms, so it does not conflict with most conventional treatments. Many patients continue their existing medications while beginning the protocol.

What changes over time, when the internal environment improves, is the need for those medications — which typically reduces as the underlying drivers are corrected. Any changes to existing medication should always be made in consultation with the prescribing physician.

Yes — not because diet causes HS, but because gut health is one of the primary internal drivers of the chronic inflammation that sustains it. Certain foods — dairy, sugar, processed carbohydrates, fermented foods — consistently increase the inflammatory load the body is managing. When that load is reduced, the flare threshold rises.

Patients who implement the dietary changes outlined in the diet guide alongside clinical treatment typically see more stable periods between flares and slower progression of disease activity.

Stress does not cause HS, but it is one of the most consistent flare triggers in patients who already have the condition. This is because stress is not merely emotional — it is biochemical. Elevated cortisol increases systemic inflammation, disrupts gut permeability, suppresses immune regulation, and worsens hormonal balance.

A single day of high emotional stress can elevate inflammatory activity for 48 to 72 hours. This is why the management of stress — sleep, structured breathing, routine — is not optional in HS treatment; it is part of the correction environment.

The most clinically useful questions go beyond "what medication should I take" and focus instead on understanding your specific disease pattern:

• What stage of HS am I in, and what does that mean for progression?
• What are my personal internal triggers?
• Which areas are at future risk if this continues?
• How stable is my gut health, and is there a hormonal component?
• Do I need metabolic assessment?
• Which lifestyle changes will have the most impact on my case specifically?
• How can I prevent tunnelling from developing?